Accessibility Menu
 
IDEAYA Biosciences logo

IDEAYA Biosciences

(NASDAQ) IDYA

Current Price$32.70
Market Cap$2.88B
Since IPO (2019)+193%
5 Year+37%
1 Year+100%
1 Month-5%

IDEAYA Biosciences Financials at a Glance

Market Cap

$2.88B

Revenue (TTM)

$218.71M

Net Income (TTM)

$113.70M

EPS (TTM)

$-1.30

P/E Ratio

-25.12

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$32.70

Volume

694,227.887

Open

$32.02

Previous Close

$32.74

Daily Range

$31.91 - $33.45

52-Week Range

$13.45 - $39.28

IDYA: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IDEAYA Biosciences

Industry

Biotechnology

Employees

145

CEO

Yujiro S. Hata, MBA

Headquarters

South San Francisco, CA 94080, US

IDYA Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

-73%

Net Income Margin

-52%

Return on Equity

-11%

Return on Capital

-15%

Return on Assets

-10%

Earnings Yield

-3.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.88B

Shares Outstanding

87.81M

Volume

694.23K

Short Interest

0.00%

Avg. Volume

921.94K

Financials (TTM)

Gross Profit

$214.12M

Operating Income

$159.31M

EBITDA

$154.72M

Operating Cash Flow

$71.10M

Capital Expenditure

$2.37M

Free Cash Flow

$73.47M

Cash & ST Invst.

$639.39M

Total Debt

$27.91M

IDEAYA Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$10.88M

+55.4%

Gross Profit

$9.68M

+52.3%

Gross Margin

88.99%

N/A

Market Cap

$2.88B

N/A

Market Cap/Employee

$21.95M

N/A

Employees

131

N/A

Net Income

$83.27M

+36.1%

EBITDA

$93.37M

+28.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$583.90M

-11.1%

Accounts Receivable

$5.97M

+199000.0%

Inventory

$0.00

N/A

Long Term Debt

$55.15M

+192.2%

Short Term Debt

$339.00K

+13.8%

Return on Assets

-10.25%

N/A

Return on Invested Capital

-15.17%

N/A

Free Cash Flow

$90.83M

+26.0%

Operating Cash Flow

$90.50M

+25.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BEAMBeam Therapeutics Inc.
$24.66+1.82%
ADPTAdaptive Biotechnologies Corporation
$14.81+2.63%
ZLABZai Lab Limited
$20.41+0.34%
LEGNLegend Biotech Corporation
$19.14+0.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About IDYA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.